Post Profile






Pembrolizumab new option for first line treatment of patients with advanced lung cancer and high PD-L1 expression

Pembrolizumab is set to become a new option for first line treatment of patients with advanced lung cancer and high PD-L1 expression, according to the results of the phase III KEYNOTE-024 trial.
read more

share

Related Posts


First-line pembrolizumab plus chemotherapy significantly improves outcomes in advanced NSCLC

Diseases & Conditions / Cancer : ScienceDaily: Cancer

The addition of PD-1 antibody pembrolizumab to standard first-line chemotherapy for treatment-naïve advanced non-small-cell lung cancer significantly improves response rates and progression-free survival, researchers report.

For ALK-Positive Lung Cancer, Phase III Trial Shows Crizotinib Superior To Single-Agent Chemotherapy

Health : Medical News Today

The results of a new phase III trial show that crizotinib, a targeted therapy, is a more effective treatment than standard chemotherapy for patients with advanced, ALK-positive lung cancer, researchers said at the ESMO 2012 Congress...

Significant survival gains with atezolizumab vs docetaxel for non-small-cell lung cancer

Diseases & Conditions / Cancer : ScienceDaily: Cancer

The first phase III study of PD-L1 inhibitor  atezolizumab in previously-treated non-small-cell lung cancer has seen significant improvements in survival compared to standard chemotherapy, researchers report.

Nintedanib improves progression-free survival but not overall survival in phase III trial of metastatic colorectal cancer

Diseases & Conditions / Cancer : ScienceDaily: Cancer

Nintedanib improves progression-free survival but not overall survival in patients with metastatic colorectal cancer who are not responding to standard therapies, according to results of the phase III LUME-colon 1 trial.

Ceritinib provides longer progression-free survival than chemotherapy in phase III trial of ALK rearranged lung cancer treatment

Diseases & Conditions / Cancer : ScienceDaily: Cancer

Ceritinib provides longer progression-free survival than chemotherapy in crizotinib-pre-treated patients with non-small-cell lung cancer harbouring an ALK rearrangement, according to results of the phase III ASCEND-5 study.

Comments


Copyright © 2016 Regator, LLC